rivoceranib,camrelizumab,sorafenib
bayer,jiangsu hengrui pharmaceuticals,elevar therapeutics,onyx
['sorafenib', 'hcc', 'camrelizumab', 'rivoceranib']
ph3 study of camrelizumab (anti-pd1) + rivoceranib (vegfr2-tki) vs sorafenib as 1l for #uhcc os 22.1 vs 15.2 mo (hr 0.62, p&lt;0.0001) pfs 5.6 vs 3.7 mo (hr 0.52, p&lt;0.0001) g 3 aes 80.9 vs 52.4% the io/tki combo as a new treatment option! #livertwitter #esmo22 
Scientific Communication Manager | Passionate about molecular oncology, clinical and translational research | Photo and music enthusiast | Tweets are mine